Home › Glioblastoma › New York › New York City
Pag-aaral pangklinika para sa Glioblastoma sa New York City, NY
Isang pag-aaral para sa Glioblastoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa New York City. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Nagre-recruitPhase 3
- Weill Cornell Medicine, New York
- NewYork-Presbyterian / Columbia University Irving Medical Center, New York
- Lennox Hill Hospital, New York
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Nagre-recruitPhase 2
- New York University Langone's Perlmutter Cancer Institute, New York
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Nagre-recruitPhase 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Nagre-recruitPhase 2/3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center*, New York
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Nagre-recruitPhase 2
- Columbia University Irving Medical Center, New York
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Nagre-recruitPhase 1
- Lenox Hill Hospital, New York
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Nagre-recruitPhase 1/2
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
Nagre-recruitPhase 3
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Nagre-recruitPhase 1/2
- Icahn School of Medicine at Mount Sinai - Oncology, New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus, New York
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Nagre-recruitPhase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Nagre-recruitPhase 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- at 1 pa
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Nagre-recruitPhase 1
- NYU Langone Health, New York
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Nagre-recruit
- NYU Langone Health, New York
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Nagre-recruitPhase 2
- New York Langone, New York
- Columbia University, New York
- Memorial Sloan Kettering Cancer Center, New York
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Nagre-recruitPhase 2
- Lenox Hill Hospital, New York
A Study of 177Lu-PSMA-617 in People With Gliomas
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Nagre-recruitPhase 1/2
- Lenox Hill Brain Tumor Center, New York
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Nagre-recruitPhase 3
- Lenox Hill Brain Tumor Center, New York
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Nagre-recruitPhase 1/2
- Lenox Hill Brain Tumor Center, New York
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Nagre-recruit
- Lenox Hill Brain Tumor Center, New York
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Nagre-recruit
- Lenox Hill Brain Tumor Center, New York
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Nagre-recruitPhase 1/2
- Lenox Hill Brain Tumor Center, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Nagre-recruitPhase 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Nagre-recruitPhase 2
- Lenox Hill Brain Tumor Center, New York
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, New York
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Nagre-recruitPhase 1
- Columbia University Medical Center - Herbert Irving Pavilion, New York
Pag-aaral para sa Glioblastoma sa ibang lungsod
- Boston, MA28 pag-aaral
- Houston, TX26 pag-aaral
- Los Angeles, CA24 pag-aaral
- Durham, NC20 pag-aaral
- San Francisco, CA17 pag-aaral
- Chicago, IL15 pag-aaral
- Washington, DC15 pag-aaral
- Miami, FL14 pag-aaral
- Columbus, OH14 pag-aaral
- Rochester, MN13 pag-aaral
- Jacksonville, FL13 pag-aaral
- Aurora, CO12 pag-aaral
Iba pang pag-aaral sa New York City
- Kanser sa Suso136 pag-aaral
- Non-Small Cell Lung Cancer121 pag-aaral
- Kanser (lahat ng uri)109 pag-aaral
- Kanser sa Prostate103 pag-aaral
- Metastatic Cancer93 pag-aaral
- Colorectal Cancer78 pag-aaral
- Kanser sa Ovary69 pag-aaral
- Kanser sa Baga60 pag-aaral
- Multiple Myeloma60 pag-aaral
- Kanser sa Pancreas60 pag-aaral
- Kanser ng Endometrium52 pag-aaral
- Acute Myeloid Leukemia51 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.